Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis - Top-Institutions - MDSpire

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

  • By

  • Noppacharn Uaprasert

  • Palada Pitakkitnukun

  • Nuanrat Tangcheewinsirikul

  • Thita Chiasakul

  • Ponlapat Rojnuckarin

  • December 23, 2022

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Immunology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #3

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Transplantation
    • Immunology

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Infectious Diseases

  • #5

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Hematology
    • Immunology
    • Infectious Diseases

Original Source(s)

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

  • by Noppacharn Uaprasert, Palada Pitakkitnukun, Nuanrat Tangcheewinsirikul, Thita Chiasakul, Ponlapat Rojnuckarin

  • December 23, 2022

Related Content

Clinical Epidemiology of Dengue and COVID-19 Co-infection Among the Residents in Dhaka, Bangladesh, 2021–2023: A Cross-sectional Study

MIS-C: Diagnosis, Management, and Outcomes

Safety, immunogenicity, and long COVID outcomes following inactivated COVID-19 vaccine boosters in elderly Chinese: a prospective cohort study